Cellumed Co.,Ltd. (KOSDAQ:049180)

Market Cap	118.30B +10.4%
Revenue (ttm)	148.55B +24.2%
Net Income	-21.30B
EPS	-400.81
Shares Out	83.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,662,230
Average Volume	2,329,946
Open	1,420.00
Previous Close	1,410.00
Day's Range	1,350.00 - 1,525.00
52-Week Range	542.00 - 2,975.00
Beta	1.54
RSI	45.48
Earnings Date	Mar 20, 2026

About Cellumed

Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFβ-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi whole, posterior tibialis, anterior tibialis, semitendinosus, gracilis, and peroneus longus tendons, and meniscus lateral and medial; cancellous bone ...

• Industry: Business Services, not elsewhere classified
• Founded: 1985
• Employees: 90
• Stock Exchange: KOSDAQ
• Ticker Symbol: 049180

Financial Performance

In 2024, Cellumed's revenue was 129.14 billion, an increase of 35.15% compared to the previous year's 95.55 billion. Losses were -31.55 billion, -15.42% less than in 2023.